Literature DB >> 3022054

Proliferative rates of cloned malignant mammary epithelial cells as a measure of clonal heterogeneity in human breast carcinomas.

R Schmidt-Ullrich, P S Lin, R B Mikkelsen, M M Monroe.   

Abstract

Malignant mammary epithelial cells (MMECs) were isolated from 8 human breast carcinomas and 1 adenoma as single cells or organoids and established in vitro. Depending on the cellularity of the tumor, between 9 X 10(4) and 4 X 10(6) cells were released per gram of tumor tissue. With the use of conditioned media and growth-promoting agents, a high proportion of cells (ranging from 0.5 to 11.4%) could be established in culture. A high degree of tumor cell heterogeneity in breast carcinomas was suggested by the observation that significantly different proliferative rates were found for 50 mammary epithelial cells cloned from 2 different tumors during the first subpassage in vitro prior to significant expansion of the cell colonies. The computed doubling times of these clones varied between 16 hours and more than 48 hours. The mammary epithelial nature of the cells was confirmed by their surface reactivity with monoclonal antibodies specific for MMECs. Studies on clones from 2 tumors revealed a positive correlation between proliferative rates of MMECs, their lactate production, and specific proteins synthesized as analyzed by two-dimensional macromolecular protein maps.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3022054

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  2 in total

Review 1.  The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy.

Authors:  S Mazurek; C B Boschek; E Eigenbrodt
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

2.  Cytogenetic analysis of multifocal breast carcinomas: detection of karyotypically unrelated clones as well as clonal similarities between tumour foci.

Authors:  M R Teixeira; N Pandis; G Bardi; J A Andersen; N Mandahl; F Mitelman; S Heim
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.